Dr. Wagener has more than 20 years of experience in global drug development, particularly in immune-mediated and cardiovascular indications, and has most recently been working as senior partner at TranScrip Partners LLP, acting as the strategic lead on drug programmes. In his new role, he will be responsible for Rexgenero’s cell therapy development, clinical and medical activities, and regulatory strategy.
“I have followed the development of Rexgenero’s cell therapy candidate for chronic limb-threatening ischaemia closely as it has progressed through clinical development, and I strongly believe in its potential for the treatment of this serious and life-threatening disease,” said Dr. Wagener.
“We are delighted to welcome Gilbert, who brings deep medical and scientific experience and expertise, particularly in the areas of cardiovascular diseases and cell and gene therapies. Gilbert will play a crucial role in steering our development programs through the next critical stage and beyond,” said Dupere.
Dr Wagener is a fellow of the European Society of Hypertension, a member of the European Society for Cardiology, the Working Group on Cardiovascular Pharmacology and Drug Therapy. He is also a member of the German Society of OPhysiology and German Society of Pharmacology and Toxicology.
Rexgenero is a UK-based cell and gene therapy company working to develop treatments for serious diseases, cancer and immunological disorders.